Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the effects of adjunctive brexpiprazole on symptoms of irritability in patients with major depressive disorder (MDD). METHODS: Patients diagnosed with MDD according to DSM-IV-TR criteria who had inadequate response to antidepressant treatment continued treatment with their current antidepressant for 2 weeks. Patients still having inadequate response, and with irritability, received 6 weeks of open-label treatment with their current antidepressant at the same dose and adjunctive brexpiprazole (target dose: 3 mg/d). Brexpiprazole was discontinued at week 6, and the patients continued with their antidepressant until week 10. Changes from baseline to week 6 and week 6 to week 10 were analyzed. RESULTS: This study was conducted between October 7, 2013, and July 30, 2014. Fifty-four patients were treated with adjunctive brexpiprazole. At week 6, clinically relevant improvements were observed in Sheehan Irritability Scale total (-21.1) and item 1 (irritable mood) (-3.5) scores, Kellner Symptom Questionnaire total (-24.4) and anger-hostility subscale (-7.7) scores, and 30-item Inventory of Depressive Symptomatology, clinician version (IDS-C₃₀), item 6 (irritable mood) score (-1.2). More (15 patients) stopped than developed (5 patients) anger attacks during treatment, as measured by the Anger Attacks Questionnaire. The Clinical Global Impressions-Severity of Illness score improved (-1.4), as did the depressive symptoms (IDS-C₃₀ total score, -17.8; Kellner Symptom Questionnaire depression subscale score, -7.7; and Montgomery-Asberg Depression Rating Scale total score, -14.2). Irritability symptoms worsened after brexpiprazole discontinuation, assessed at week 10. Adjunctive brexpiprazole was well tolerated. CONCLUSIONS: Adjunctive treatment with brexpiprazole may represent a strategy for patients with MDD and inadequate response to antidepressant treatment who have symptoms of irritability. TRIALS REGISTRATION: ClinicalTrials.gov identifier: NCT01942785.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Brexpiprazole, was FDA approved as an adjunctive treatment to oral antidepressants in MDD based on 3 trials which showed a significant reduction in depressive symptoms (Fava et al., 2016; Thase et al., 2015a; Thase et al., 2015b).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Fava et al., 2016
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
(1976) · Medical Entomology and Zoology · Cited by 8,899
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372
Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., Raskind, M. A., & Peskind, E. R. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181ab8c61 · Cited by 209
Fava, M., Hwang, I., Rush, A. J., Sampson, N., Walters, E. E., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.20 · Cited by 201
Fava, G. A., & Bech, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441244 · Cited by 176
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Chandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158
Cited by
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12714 · Cited by 63
Benasi, G., Fava, G. A., & Rafanelli, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506110 · Cited by 45
Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
Siwek, M., Wojtasik-Bakalarz, K., Krupa, A. J., & Chrobak, A. A. (2023) · Brain Sciences · doi:10.3390/brainsci13030397 · Cited by 50
“[57] N = 50; TRD; 6 weeks; BRX * 1–3 mg H anger in KSQ and irritability in IDS-C30; no further bouts of anger in 15 of 17 subjects; H MADRS, CGI-I, CGI-S, exacerbation after discontinuation Open-label, Davis et al.”
BackgroundBrexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
Diefenderfer, L. A., & Iuppa, C. A. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.207 · Cited by 44
“Evidence also shows improvements in irritability and work/school functioning with open-label brexpiprazole plus standard antidepressant treatment compared with placebo.(11,12)”
Metadata
- Authors
- Fava, M., Ménard, F., Davidsen, C. K., & Baker, R. A.
- Affiliations
- Lundbeck (Denmark) (DK)
- Otsuka (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-07-05
- Volume
- 77
- Issue
- 12
- Pages
- 1695-1701
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2460591166
- Cited by
- 23
- References
- 23
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 1
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- brexpiprazole, major depressive disorder, irritability, adjunctive therapy, inadequate response to antidepressants, irritable mood, anger attacks, antidepressant non-response, treatment discontinuation
- MeSH terms
- Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Irritable Mood, Male, Middle Aged, Thiophenes, Quinolones, Outcome Assessment, Health Care, Serotonin Agents, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study. https://app.cochat.ai/papers/10.4088/jcp.15m10470
- The paper
- Fava, M., Ménard, F., Davidsen, C. K., & Baker, R. A. (2016). Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.15m10470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.